Evidence map›Paper›PMID 34753503›Full record

ArticleCardiovascular ultrasound2021

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.

Nathalie I Bouwer, Crista Liesting, Marcel J M Kofflard, Jasper J Brugts, Marc C J Kock, Jos J E M Kitzen, Mark-David Levin, Eric Boersma

Abstract read
In one paragraph

Article in Cardiovascular ultrasound, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nathalie I BouwerDepartment of Internal Medicine , Albert Schweitzer Hospital, 3300 AK, Dordrecht, The Netherlands. n.i.bouwer@asz.nl.ORCID http://orcid.org/0000-0002-2048-2233
Crista LiestingDepartment of Cardiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Marcel J M KofflardDepartment of Cardiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Jasper J BrugtsDepartment of Cardiology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Marc C J KockDepartment of Radiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Jos J E M KitzenDepartment of Internal Medicine , Albert Schweitzer Hospital, 3300 AK, Dordrecht, The Netherlands.
Mark-David LevinDepartment of Internal Medicine , Albert Schweitzer Hospital, 3300 AK, Dordrecht, The Netherlands.
Eric BoersmaDepartment of Cardiology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aimed to study the predictive value of early two-dimensional echocardiography (2DE) speckle tracking (ST) for left ventricular ejection fraction (LVEF) changes during trastuzumab treatment for HER2-positive breast cancer.

methodsHER2-positive breast cancer patients receiving trastuzumab, with or without anthracycline, underwent 2DE-ST at baseline and after 3 and 6 months (m) trastuzumab. Cardiac magnetic resonance (CMR) imaging (with ST) was performed at baseline and 6 m. We studied the correlation between 2DE-ST- and CMR-derived global longitudinal strain (GLS) and global radial strain (GRS) measured at the same time. Additionally, we associated baseline and 3 m 2DE-ST measurements with later CMR-LVEF, and with cardiotoxicity, defined as CMR-LVEF < 45% and/or absolute decline > 10% during trastuzumab.

resultsForty-seven patients were included. Median baseline LVEF was 60.4%. GLS measurements based on 2DE-ST and CMR showed weak correlation (Pearson's r = 0.33; p = 0.041); GRS measurements were uncorrelated (r = 0.09; p = 0.979). 2DE-LVEF at baseline and 3 m, and 2DE-ST-GLS at 3 m were predictive of CMR-LVEF at 6 m. In contrast, the change in 2DE-ST-GLS at 3 m was predictive of the change in CMR-LVEF at 6 m, whereas the change in 2DE-LVEF was not. Importantly, the 11 patients who developed cardiotoxicity (28%) had larger 2DE-ST-GLS change at 3 m than those who did not (median 5.2%-points versus 1.7%-points; odds ratio for 1% difference change 1.81, 95% confidence interval 1.11-2.93; p = 0.016; explained variance 0.34).

conclusionsCorrelations between 2DE-ST and CMR-derived measurements are weak. Nevertheless, ST-measurements appeared useful to improve the performance of 2DE in predicting LVEF changes after 6 m of trastuzumab treatment.

Indexed as

Breast NeoplasmsTrastuzumabVentricular Dysfunction, LeftEchocardiographyFemaleHumansMagnetic Resonance ImagingProspective StudiesStroke VolumeVentricular Function, LeftTrastuzumabCardiac MRIHER2-positive breast cancerSpeckle tracking echocardiographyStrain imagingTrastuzumab

Identifiers

PMID34753503
PMCPMC8576921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.